商品描述
Modified UTP for the use in mRNA synthesis.
Use this modified UTP for the synthesis of mRNA for therapeutics or vaccines. It is designed to meet the specific needs of the pharmaceutical industry (fit-for-purpose):
animal-origin-free (AOF)
ß-Lactam-antibiotic free
extended testing for impurities
manufactured under GMP
Application
This modified UTP can replace UTP in in-vitro-transcription reactions, e.g. for manufacturing mRNA therapeutics and vaccines. This RNA modification provides enhanced protein expression and reduced unwanted immunogenicity against the mRNA molecule itself. Its efficacy has been proven by its use in COVID-19 vaccines.
Properties
Nomenclature: N1-methyl-pseudouridine-5'-triphosphate
CAS Number: 1428903-59-6 (free acid)
Formula: C10H17N2O15P3
Molecular weight: 498.2 D
Specifications
Appearance: Clear, colorless solution
pH value: 8.1–8.5
N1-Methyl-UTP (A271; pH 7.0 ε= 7.3 [L x mmol–1 x cm–1]): 100–110 mmol/L
N1-Methyl-UTP (HPLC): ≥ 98.5 area%
Identity (HPLC-MS): Corresponds
DNases/RNases: Negative
Nicking activity: Negative
Functional transcription assay: Corresponds to specification
Proteases: Not detectable
Exonucleases: Not detectable
Endotoxins: ≤ 2 EU/mL
Bioburden: ≤ 5 CFU/mL
Heavy metals (Ni, Co, V): ≤ 10 ppm
Stability: At –15 to –25°C within specification range for 24 months.
Regulatory Disclaimer
For further processing only.